LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | HG-5-113-01 | 10 | uM | LJP5 | 72 | hr | 1235 | 883 | 4267 | 0.2073 | -0.1712 |
| MCF7 | WZ3105 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 883 | 4267 | 0.2072 | -0.1710 |
| MDA-MB-231 | Geldanamycin | 10 | uM | LJP5 | 72 | hr | 868 | 603 | 3410 | 0.1773 | -0.1688 |
| BT-20 | Pelitinib | 10 | uM | LJP5 | 72 | hr | 1657 | 1202 | 5588 | 0.2152 | -0.1674 |
| Hs 578T | CGP60474 | 10 | uM | LJP6 | 72 | hr | 929 | 669 | 3216 | 0.2081 | -0.1674 |
| SK-BR-3 | QL-XII-47 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1164 | 3643 | 0.3202 | -0.1673 |
| BT-20 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1217 | 5383 | 0.2261 | -0.1671 |
| BT-20 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 1217 | 5383 | 0.2262 | -0.1665 |
| BT-20 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1218 | 5383 | 0.2267 | -0.1661 |
| BT-20 | A443654 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 1225 | 5383 | 0.2275 | -0.1638 |
| SK-BR-3 | A443654 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1173 | 3643 | 0.3221 | -0.1636 |
| MDA-MB-231 | Canertinib | 10 | uM | LJP6 | 72 | hr | 868 | 617 | 3556 | 0.1728 | -0.1616 |
| MCF7 | WZ3105 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 904 | 4267 | 0.2117 | -0.1614 |
| BT-20 | QL-X-138 | 10 | uM | LJP6 | 72 | hr | 1657 | 1231 | 5383 | 0.2286 | -0.1614 |
| BT-20 | Torin1 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1240 | 5383 | 0.2297 | -0.1607 |
| MCF7 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 916 | 4056 | 0.2260 | -0.1601 |
| BT-20 | GSK1059615 | 1.11 | uM | LJP5 | 72 | hr | 1657 | 1221 | 5588 | 0.2186 | -0.1599 |
| BT-20 | GDC-0980 | 10 | uM | LJP5 | 72 | hr | 1657 | 1222 | 5588 | 0.2188 | -0.1597 |
| Hs 578T | HG-6-64-01 | 10 | uM | LJP6 | 72 | hr | 929 | 682 | 3216 | 0.2120 | -0.1590 |
| MCF7 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 906 | 4267 | 0.2127 | -0.1589 |
| BT-20 | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1241 | 5383 | 0.2301 | -0.1587 |
| MDA-MB-231 | Alvocidib | 0.37 | uM | LJP6 | 72 | hr | 868 | 611 | 3556 | 0.1720 | -0.1586 |
| MDA-MB-231 | Alvocidib | 3.33 | uM | LJP6 | 72 | hr | 868 | 612 | 3556 | 0.1726 | -0.1584 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1172 | 3772 | 0.3108 | -0.1583 |
| MDA-MB-231 | Fedratinib | 10 | uM | LJP5 | 72 | hr | 868 | 618 | 3410 | 0.1819 | -0.1582 |